Related Experiment Video

Updated: Aug 24, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction

E L Grove1, T F Ørntoft, J F Lassen

  • 1Department of Cardiology, Aarhus University Hospital, Skejby Sygehus, Denmark.

Journal of Internal Medicine
|May 19, 2004
PubMed
Abstract

Insights

The Pl(A2) platelet polymorphism is linked to a higher risk of myocardial infarction (MI) in Scandinavian populations. This finding may influence antiplatelet therapy decisions for MI patients.

Area of Science:

  • Cardiovascular Genetics
  • Platelet Biology
  • Epidemiology

Background:

  • Platelet glycoprotein (GP) receptor IIb/IIIa is crucial in myocardial infarction (MI) development.
  • The Pl(A2) polymorphism in the GP receptor IIb/IIIa gene exhibits geographical variation.
  • Previous studies suggest Pl(A2) may increase platelet aggregation and MI risk.

Purpose of the Study:

  • To investigate the association between the Pl(A2) polymorphism and MI in a large Scandinavian population.
  • To determine the prevalence of Pl(A2) in healthy individuals and patients with coronary artery disease (CAD).

Main Methods:

  • A case-control study design was employed.
  • Included 1191 healthy individuals and 1019 patients with angiographically verified CAD (529 with prior MI).
  • Matched participants for age, race, and sex.

Main Results:

  • Pl(A2) prevalence was 28% in healthy individuals, 28% in CAD patients without MI, and 35% in CAD patients with MI.
  • A significant association was found between Pl(A2) and MI risk (P=0.002).
  • A graded relationship between Pl(A2) allele count and MI risk was observed (P=0.011), with a significant interaction with serum cholesterol.

Conclusions:

  • The Pl(A2) polymorphism is significantly associated with increased MI risk in a Scandinavian population.
  • No significant association was found between Pl(A2) and overall CAD risk.
  • Pl(A2) genotyping may inform antiplatelet therapy strategies for MI patients.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...